Q1 Earnings Estimate for NAMS Issued By Leerink Partnrs

NewAmsterdam Pharma (NASDAQ:NAMS) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for NewAmsterdam Pharma in a research note issued to investors on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings per share of ($0.20) for the quarter. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($1.15) EPS and FY2027 earnings at ($1.20) EPS.

NAMS has been the subject of a number of other reports. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Scotiabank raised their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a report on Wednesday, December 11th. Finally, Piper Sandler restated an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $36.20.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $25.50 on Friday. The business’s 50 day simple moving average is $21.31 and its 200 day simple moving average is $18.95. NewAmsterdam Pharma has a 1 year low of $10.50 and a 1 year high of $27.29.

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the completion of the transaction, the insider now directly owns 11,150,461 shares of the company’s stock, valued at approximately $283,110,204.79. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 353,542 shares of company stock valued at $8,599,328 over the last ninety days. 19.50% of the stock is owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of NAMS. Frazier Life Sciences Management L.P. boosted its holdings in shares of NewAmsterdam Pharma by 5.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock valued at $213,396,000 after acquiring an additional 628,251 shares in the last quarter. Janus Henderson Group PLC raised its position in NewAmsterdam Pharma by 51.1% in the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock valued at $25,607,000 after purchasing an additional 520,772 shares during the last quarter. Millennium Management LLC raised its position in NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after purchasing an additional 217,902 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of NewAmsterdam Pharma by 8.9% during the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock valued at $16,937,000 after purchasing an additional 83,115 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C grew its holdings in shares of NewAmsterdam Pharma by 30.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock worth $16,698,000 after purchasing an additional 202,250 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.